Association between the expression of IL-10 and T cell activation proteins loss in early breast cancer patients

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 2, 2009, Pages 255-264

  Llanes Fernández, Leticia ^a   Del Carmen Arango Prado, Maria ^a   Alcocer González, Juan Manuel ^b   Guerra Yi, Marta Elena ^a   Franco Odio, Sonia ^a   Camacho Rodríguez, Rolando ^a   Madrid Marina, Vicente ^c   Tamez Guerra, Reyes ^b   Rodríguez Padilla, Cristina ^b  

^a INSTITUTO NACIONAL DE ONCOLOGÍA Y RADIOBIOLOGÍA   (Cuba)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^c INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

Breast cancer; Cancer immunology; Cytokines; T cell activating molecules

Indexed keywords

ASE 1 PROTEIN, HUMAN; ASE-1 PROTEIN, HUMAN; CD3 ANTIGEN; CYTOKINE; INTERFERON; INTERLEUKIN 10; INTERLEUKIN DERIVATIVE; MESSENGER RNA; PROTEIN TYROSINE KINASE; RNA; SIGNAL PEPTIDE;

ARTICLE; BREAST TUMOR; CANCER STAGING; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; LYMPH NODE; LYMPHOCYTE ACTIVATION; MASTECTOMY; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ANTIGENS, CD3; BREAST NEOPLASMS; CYTOKINES; FEMALE; HUMANS; INTERFERONS; INTERLEUKIN-10; INTERLEUKINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPH NODES; LYMPHOCYTE ACTIVATION; MASTECTOMY; NEOPLASM STAGING; PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; T-LYMPHOCYTES;

EID: 65849456561     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-008-0446-7     Document Type: Article

References (53)

1. Arase H, Suenaga T, Arase N, Kimura Y, Ito K, Shina R et al (2001) Negative regulation of expression and function of FcγRIII by CD3ζ in murine NK cells. J Immunol 166:21-25
2. 4+ human T cell clone by the autologous MHC class II+ melanoma. Int Immunol 5:1501-1508. doi:10.1093/intimm/5.12.1501
3. Beissert S, Hosoi J, Grabbe S, Asahina A, Granstein RD (1995) IL-10 inhibit tumor antigen presentation by epidermal antigen-presenting cells. J Immunol 154:1280-1286
4. Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E et al (2004) Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 10:7157-7162. doi:10.1158/1078-0432.CCR-04-0812
5. von BernstorV W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C et al (2001) Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7:925s-932s
6. Chakraborty G, Rangaswami H, Jain S, Kundu GC (2006) Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis. J Biol Chem 281:11322-11331. doi:10.1074/jbc.M512546200
7. Chomczynski PA (1993) Reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 51:532-540
8. Favre N, Bordmann G, Rudin W (1997) Comparison of cytokine measurements using ELISA, ELISPOT and semi-quantitative RTPCR. J Immunol Methods 204:57-66. doi:10.1016/S0022-1759(97)00033-1
9. Furukawa T, Itoh M, Krueger NX, Streuli M, Saito H (1994) Specific interacction of the CD45 protein-tyrosine phosphatase with tyrosine- phosphorylated CD3 ζ chain. Proc Natl Acad Sci USA 91:10928-10932. doi:10.1073/pnas.91.23.10928
10. Gratama JW, Zea AH, Bolhuis RL, Ochoa AC (1999) Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer alter combination immunotherapy. Cancer Immunol Immunother 48:263-269. doi:10.1007/s002620050574
11. Green AR, Green VL, White MC, Speirs V (1997) Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: Identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer 72:937-941. doi:10.1002/(SICI) 1097-0215(19970917)72:6〈937::AID- IJC3〉3.0.CO;2-Q
12. Hadden JW (1999) Review article the immunology and immunotherapy of breast cancer: an update. Int J Immunopharmacol 21:79-101. doi:10.1016/S0192- 0561(98)00077-0
13. Halak BK, Maguirre HC Jr, Lattime EC (1999) Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 59:911-917
14. Hermiston ML, Xu Z, Majeti R, Weiss A (2002) Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases. J Clin Invest 109:9-14
15. Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H et al (1995) Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 55:3847-3853
16. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Higashi H, Inashige H et al (2002) CD3-zeta chain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients. Cancer 94:1437-1442. doi:10.1002/cncr.10346
17. Ishigami S, Natsugoe S, Miyazono F, Tokuda K, Nakajo A, Matsumoto M et al (2004) CD3 zeta expression of regional lymph node and peripheral blood lymphocytes in gastric cancer. Anticancer Res 24:2123-2126
18. Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, Lee PP (2005) ProWle of immune cells in axillary lymph nodes predicts diseasefree survival in breast cancer. PLoS Med 2(9):e284. doi:10.1371/journal.pmed.0020284
19. Krishnan S, Farber DL, Tsokos GC (2003) T cell rewiring in differentiation and disease. J Immunol 171:3325-3331
20. Kurtzman SH, Anderson KH, Wang Y, Miller LJ, Renna M, Stankus M et al (1999) Cytokines in human breast cancer: IL-1alfa and IL-1beta expression. Oncol Rep 6:65-70
21. Kuss I, Saito T, Johnson JT, Whiteside TL (1999) Clinical signiWcance of decreased ζ chain expression in peripheral blood lymphocyte of patients with head neck cancer. Clin Cancer Res 5:329-334
22. Kuss I, Rabinowich H, Gooding W, Edwards R, Whiteside TL (2002) Expression of zeta in T cells prior to interleukin-2 therapy as a predictor of response and survival in patients with ovarian carcinoma. Cancer Biother Radiopharm 17:631-640. doi:10.1089/108497802320970235
23. La Gruta NL, Liu H, Dilioglou S, Rhodes M, Wiest DL, Vignali DAA (2004) Architectural changes in the TCR:CD3 complex induced by MHC:peptide ligation. J Immunol 172:3662-3669
24. Llanes-Fernández L, Álvarez-Goyanes RI, Arango-Prado MC, Alcocer-González JM, Mojarrieta JC, Perez XE et al (2006) Relationship between IL-10 and tumor markers in breast cancer patients. Breast 15:482-489. doi:10.1016/j.breast.2005.09.012
25. Maki A, Matsuda M, Asakawa M, Kono H, Fujii H, Matsumoto Y (2003) Decreased CD3 zeta molecules of T lymphocytes from patients with hepatocellular carcinoma associated with hepatitis C virus. Hepatol Res 27:272-278. doi:10.1016/S1386-6346(02)00315-7
26. Marrogi AJ, Munshi A, Merogi AJ, Ohadike Y, El-Habashi A (1997) Study of tumor inWltrating lymphocytes and transforming growth factor-beta as prognostic factor in breast carcinoma. Int J Cancer 74:492-501. doi:10.1002/(SICI)1097- 0215(19971021)74:5〈492::AID-IJC3〉3.0.CO;2-Z
27. Matache C, Stefanescu M, Onu A, Tanaseanu S, Matei I, Frade R et al (1999) p56lck activity and expression in peripheral blood lymphocytes from patients with systemic lupus erythematosus. Autoimmunity 29:111-120
28. Matsuda M, Petersson M, Lenkei R, Taupin JL, Magmesson I, Mellstedt H et al (1995) Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-inWltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the desease. Int J Cancer 61:765-772. doi:10.1002/ijc.2910610605
29. Matsuda M, Ulfgren AK, Lenkei R, Petersson M, Ochoa AC, Lindblad S et al (1998) Decreased expression of signal-transducing CD3 z chains in T cells from the joints and peripheral blood of rheumatoid arthritis patients. Scand J Immunol 47:254-262. doi:10.1046/j.1365-3083.1998.00296.x
30. Merendino RA, Gangemi S, Misefari A, Arena A, Capozza AB, Chillemi S et al (1999) Interleukin-12 and interleukin-10 production by mononuclear phagocytic cells from breast cancer patients. Immunol Lett 68:355-358. doi:10.1016/S0165-2478(99)00067-X
31. Mizoguchi H, O'Shea JJ, Longo DL, Loeffer CM, McVicar DW, Ochoa AC (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795-1798. doi:10.1126/science.1465616
32. Muller D, Lang S, Roskrow M, Wollenberg B (2002) The expression of zeta-chain of the T cell receptor as prognostic marker for patients with head and neck cancer. Laryngorhinootologie 81:516-520. doi:10.1055/s-2002-33289
33. Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H et al (1993) Decreased expression of the signal transducing ζ chains in tumor-inWltrating T cells and NK cells of patients with colorectal carcinoma. Cancer Res 53:5610-5612
34. lck expression in T lymphocytes from type 1 diabetic patients. J Immunol 165:5874-5883
35. Nieland JD, Loviscek K, Kono K, Albain KS, McCall AR, Potkul RK et al (1998) PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCRζ expression but are functionally impaired. J Immunother 21:317-322. doi:10.1097/00002371-199807000-00009
36. Palacios EH, Weiss A (2004) Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 23:7990-8000. doi:10.1038/sj.onc.1208074
37. Pantschenko AG, Pushkar I, Anderson KH, Wang Y, Miller LJ, Kurtzman SH et al (2003) The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol 23:269-284
38. Parkin DM, Fernández LM (2006) Use of statistics to assess the global burden of breast cancer. Breast J 12:S70-S80. doi:10.1111/j.1075-122X. 2006.00205.x
39. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
40. Poindexter NJ, Sahin A, Hunt KK, Grimm EA (2004) Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res 6:R408-R415. doi:10.1186/bcr808
41. al-Ramadi BK, Nakamura T, Leitenberg D, Bothwell AL (1996) Defficient expression of p56(lck) in Th2 cells leads to partial TCR signaling and a dysregulation in lymphokine mRNA levels. J Immunol 157:4751-4761
42. Rao VS, Dyer CE, Jameel JK, Drew PJ, Greenman J (2006) Potential prognostic and therapeutic roles for cytokines in breast cancer. Oncol Rep 15:179-185
43. Reichert TE, Rabinowich H, Johnson JT, Whiteside TL (1998) Mechanisms responsible for signaling and functional defects. J Immunother 21:295-306. doi:10.1097/00002371-199807000-00007
44. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL (2002) Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-inWltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 8:3137-3145
45. Rosen HR, Ausch C, Reinerova M, Zaspin E, Renner K, Rosen AC et al (1998) Activated lymphocytes from breast cancer patients express the characteristics of type 2 helper cells -a possible role for breast cancer-associated p43. Cancer Lett 127:129-134. doi:10.1016/S0304-3835(98)00017-2
46. Salvadori S, Martinelli G, Zier K (2000) Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 164:2214-2220
47. Taylor DD, Edwards RP, Case CR, Gercel-Taylor C (2004) Modulation of CD3-zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients. Gynecol Oncol 94:54-60. doi:10.1016/j.ygyno.2004.03.032
48. Toomey D, Harmey J, Condron C, Kay E, Bouchier-Hayes D (1999) Phenotyping of immune cell inWltrates in breast and colorectal tumours. Immunol Invest 28:29-41. doi:10.3109/08820139909022721
49. Venetsanakos E, Beckman I, Bradley J, Skinner JM (1997) High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J Cancer 75:1826-1830
50. Wong PY, Staren ED, Tereshkova N, Braun DP (1998) Functional analysis of tumor-inWltrating leukocytes in breast cancer patients. J Surg Res 76:95-103. doi:10.1006/jsre.1998.5301
51. Yang F, Stenoien DL, Strittmatter EF, Wang J, Ding L, Lipton MS et al (2006) Phosphoproteome proWling of human skin Wbroblast cells in response to low- and high-dose irradiation. J Proteome Res 5:1252-1260. doi:10.1021/ pr060028v
52. Zanussi S, Vaccher E, CaVau C, Pratesi C, Crepaldi C, Bortolin MT et al (2003) Interferon-gamma secretion and perforin expression are impaired in CD8+ T lymphocytes from patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother 52:28-32
53. Zea AH, Ochoa MT, Ghosh P, Longo DL, Alvord WG, Valderrama L et al (1998) Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy. Infect Immun 66:499-504